Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma
- PMID: 11106082
- DOI: 10.1038/modpathol.3880228
Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma
Abstract
ERBB2 (HER-2/neu) amplification and/or overexpression are associated with poor prognosis in node-positive breast carcinoma. Its prognostic value in node-negative cases and its predictive value for response to chemotherapy remain controversial. This may be related to the use of molecular methods, which are sensitive to dilution of tumor material by normal cells, or the use of nonstandardized immunohistochemistry (IHC) procedures, for the determination of the ERBB2 gene status. In addition, new therapeutic approaches that target the cells overexpressing ERBB2 are under development. These perspectives necessitate a reliable evaluation of the status of ERBB2 in individual tumors before the application of specific therapeutic strategies. Fluorescent in situ hybridization (FISH) and IHC allow the evaluation of the ERBB2 status specifically in tumor cells on archival material. We have analyzed a series of 100 invasive ductal breast carcinomas without lymph node invasion both by IHC, using the CB11 monoclonal antibody and a sensitive Auidin Biotin Complex (ABC) immunodetection system, and by FISH, using the Oncor Inform HER-21neu (ERBB2) gene amplification detection system as reference technique. Complete concordance between the results of FISH and IHC was seen in 98% of the cases. ERBB2 amplification (more than four signals per nucleus) was observed in 12 of the 100 cases, and all but one showed an overexpression of the protein (membrane staining) by IHC. Conversely, ERBB2 expression was present in one case without gene amplification. In conclusion, ERBB2 overexpression detected by IHC is highly correlated to gene amplification detected by FISH. Thus, under standardized conditions, IHC is a reliable and economical test to assess the ERBB2 status in tumors. The use of FISH could be limited to the verification of the status of tumors displaying a weak membrane immunostaining.
Similar articles
-
Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.Mod Pathol. 2000 Jan;13(1):37-45. doi: 10.1038/modpathol.3880007. Mod Pathol. 2000. PMID: 10658908
-
Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.Neoplasma. 2006;53(5):393-401. Neoplasma. 2006. PMID: 17013533
-
Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.Breast J. 2005 Nov-Dec;11(6):433-9. doi: 10.1111/j.1075-122X.2005.00125.x. Breast J. 2005. PMID: 16297088
-
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Ann Pathol. 2011. PMID: 22172120 Review. French.
-
HER-2/neu (c-erb-B2) gene and protein in breast cancer.Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S53-67. Am J Clin Pathol. 1999. PMID: 10396301 Review.
Cited by
-
Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer.World J Gastrointest Surg. 2024 May 27;16(5):1395-1406. doi: 10.4240/wjgs.v16.i5.1395. World J Gastrointest Surg. 2024. PMID: 38817281 Free PMC article.
-
HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review.Int J Mol Sci. 2023 Feb 10;24(4):3590. doi: 10.3390/ijms24043590. Int J Mol Sci. 2023. PMID: 36834998 Free PMC article. Review.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach.Virchows Arch. 2019 Dec;475(6):709-725. doi: 10.1007/s00428-019-02635-4. Epub 2019 Aug 12. Virchows Arch. 2019. PMID: 31407032
-
Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains.Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3103-3110. doi: 10.22034/APJCP.2017.18.11.3103. Asian Pac J Cancer Prev. 2017. PMID: 29172286 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous